The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia
详细信息 查看全文
- 作者：Delphine Manzonia ; b ; Ré ; gine Catalloa ; Amel Chebela ; Lucile Baseggioa ; b ; Anne-Sophie Michalletc ; Olivier Roualdesa ; b ; Jean-Pierre Magaudb ; Gilles Sallesa ; c ; Martine Ffrencha ; b ; c ; ffrenchma@gmail.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：BCR ; B-cell receptor ; BTK ; Bruton tyrosine kinase ; CLL ; chronic lymphocytic leukemia ; DXM ; dexamethasone ; GR ; glucocorticoid receptor ; CDK ; cyclin-dependant kinase ; PBL ; peripheral blood lymphocytes ; ROS ; reactive oxygen species
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：47
- 期：Complete
- 页码：1-7
- 全文大小：1719 K
文摘
- •
Dexamethasone (DXM) potentiated ibrutinib effects in normal and malignant B-cells.
- •
DXM intensified cell cycle inhibition induced by ibrutinib in B-cells.
- •
The decrease in DNA damage induced by ibrutinib was reinforced by DXM.
- •
DXM/ibrutinib combination could be valuable in lymphoid malignancy treatment.